Component

Collagen- and arachidonic-acid-induced human platelet aggregation

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation.

    Experimental context and source evidence
    dose
    Eugenol 2 micromolar
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm
    limitations
    Ex-vivo platelet inhibition and mouse thrombosis do not establish oral antithrombotic efficacy or bleeding safety in humans.
    nutrient_topic
    Eugenol chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Eugenol
    organism
    Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm
    plain_language
    At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation.
    primary_references
    Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models. (2024). https://pubmed.ncbi.nlm.nih.gov/38396774/ DOI: 10.3390/ijms25042098
    route
    In vitro; mouse intervention
    tissue
    Agonist-specific platelet aggregation

    Eugenol: mechanism of action and interactions (2026-09-20) · lines 11–20

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm · source_derived_draft · unverified_draft

    ## eugenol-platelet-agonist-selectivity At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation. Model/species: Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm Tissue/system: Agonist-specific platelet aggregation Exposure: Eugenol 2 micromolar Route: In vitro; mouse intervention Duration: Acute Limits: Ex-vivo platelet inhibition and mouse thrombosis do not establish oral antithrombotic efficacy or bleeding safety in humans. Primary reference: Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models. (2024). https://pubmed.ncbi.nlm.nih.gov/38396774/ DOI: 10.3390/ijms25042098 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards